Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."

Recent & Breaking News (NDAQ:OXGN)

OXiGENE Reports Second Quarter 2015 Financial Results

GlobeNewswire August 4, 2015

OXiGENE to Host Second Quarter Financial Results Conference Call and Webcast

GlobeNewswire July 28, 2015

OXiGENE Appoints Matthew M. Loar as Chief Financial Officer

GlobeNewswire July 20, 2015

OXiGENE Appoints Matthew M. Loar as Chief Financial Officer

GlobeNewswire July 20, 2015

OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer

GlobeNewswire June 1, 2015

OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia

GlobeNewswire May 26, 2015

OXiGENE Appoints Bill Schwieterman, M.D., as President and Chief Executive Officer

GlobeNewswire May 12, 2015

OXiGENE Reports First Quarter 2015 Financial Results

GlobeNewswire April 30, 2015

OXiGENE Announces First Quarter Financial Results Conference Call and Webcast

GlobeNewswire April 20, 2015

OXiGENE Announces Participation in Upcoming Investor and Medical Conferences

GlobeNewswire April 2, 2015

OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering

GlobeNewswire March 20, 2015

OXiGENE Reports Financial Results for 2014

GlobeNewswire March 17, 2015

OXiGENE Announces 2014 Financial Results Conference Call and Webcast

GlobeNewswire March 4, 2015

OXiGENE Announces Presentation and Webcast at the 27th Annual ROTH Conference on March 11th

GlobeNewswire February 24, 2015

OXiGENE Announces Presentation and Webcast at the 17th Annual BIO CEO & Investor Conference on February 10th

GlobeNewswire January 26, 2015

OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting

GlobeNewswire November 20, 2014

OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies

GlobeNewswire November 17, 2014

OXiGENE Reports Third Quarter 2014 Financial Results

GlobeNewswire November 12, 2014

OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer

GlobeNewswire November 10, 2014

OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast

GlobeNewswire October 22, 2014